Dual triggering of DNA binding and fluorescence via photoactivation of a dinuclear ruthenium(II) arene complex

Redox-Induced Intramolecular C-C Coupling of Acyclic Bis(2-pyridylmethylene)ethylenediamine on a Ru(acac)2 Platform

The paper documents redox-triggered C-C coupling of acyclic N,N'-bis(2-pyridylmethylene)ethylenediamine (BPE) to yield 2,3-bis(2-pyridyl)pyrazine (DPP) upon coordination to an electron-rich {Ru(acac)₂} (acac = acetylacetonate) unit. This led to DPP-bridged [{Ru(acac)₂}₂(DPP)]^0/+ (2 and [2]ClO₄) along with the unperturbed BPE-bridged [{Ru(acac)₂}₂(BPE)] (1). On the contrary, electron-poor {Ru(Cl)(H)(CO)(PPh₃)₃} yielded BPE-bridged [3](ClO₄)₂ as an exclusive product. Synergistic metal (Ru)-ligand (BPE) redox participation toward chemical noninnocence of the Schiff base ligand and DPP-mediated electronic communication in Ru^IIRu^III-derived [2]ClO₄ are addressed.

The Development of Ru(II)-Based Photoactivated Chemotherapy Agents

Photoactivated chemotherapy (PACT) is a novel cancer treatment method that has drawn increasing attention due to its high selectivity and low side effects by spatio-temporal control of irradiation. Compared with photodynamic therapy (PDT), oxygen-independent PACT is more suitable for treating hypoxic tumors. By finely tuning ligand structures and coordination configurations, many Ru(II) complexes can undergo photoinduced ligand dissociation, and the resulting Ru(II) aqua species and/or free ligands may have anticancer activity, showing their potential as PACT agents. In this mini-review, we summarized the progress in Ru(II)-based PACT agents, as well as challenges that researchers in this field still face.

DNA targeting half sandwich Ru(II)-p-cymene-N^N complexes as cancer cell imaging and terminating agents: influence of regioisomers in cytotoxicity

For diagnosing and annihilating cancer in the human body, herein, we have adopted a one pot convenient synthetic protocol to synthesize a library of half sandwich Ru(ii)-p-cymene-N^N complexes under continuous sonication and isolated their regioisomers by preparative thin layer chromatography followed by justification of stability using DFT. The present work has resulted in a library of ruthenium arene complexes and their isolated regioisomers following environmentally benign green processes and their screening of anticancer activity in terms of cytotoxicity and selectivity against cancer cell lines where [(η6-p-cymene)RuCl{2-(5,6-dichloro-1H-benzo[d]imidazole-2-yl)quinolone}] (11j) has been elicited to be significantly more potent as well as selective in Caco-2 and HeLa cell lines than the normal HEK-293 cell line compared to cisplatin and it has even shown marked cytotoxicity against the more aggressive HT-29 colorectal cancer cell line being capable of producing oxidative stress or arresting the cell cycle. Moreover, these types of Ru(ii)-arene complexes exhibited excellent binding efficacy with DNA and the compounds [(η6-p-cymene)RuCl{5-chloro-2-(6-(4-chlorophenyl)pyridin-2-yl)benzo[d]thiazole}]PF6 (8l4), [(η6-p-cymene)Ru-2-(6-(benzofuran-2-yl)pyridin-2-yl)-5-chlorobenzo[d]thiazole (8l9) and [(η6-p-cymene)RuCl{2-(6-nitro-1H-benzo[d]imidazol-2-yl)quinolone}]Cl (11f') and might be applied for cancer theranostic treatment due to their good fluorescence properties and remarkable potency.

Intramolecular Hydrogen Bonding: A Key Factor Controlling the Photosubstitution of Ruthenium Complexes

Photosubstitution reactions of ruthenium complexes with pyrazole ligands, cis-[Ru(bpy)₂(pzH)₂]²⁺ (1a), cis-[Ru(bpy)₂(pz)(pzH)]⁺ (1b), and cis-[Ru(bpy)₂(pz)₂]⁰ (1c) (pzH = pyrazole, bpy = 2,2'-bipyridine), were investigated. Dicationic complex 1a was deprotonated to 1b using moderate base (pK_a = 15.2, MeCN), while the second deprotonation to give 1c required more severe conditions (pK_a = 26.9). Monocationic complex 1b possessed an N-H···N-type intramolecular hydrogen bond between the pyrazole and pyrazolate ligands, as corroborated by the solid-state crystal structure. The photosubstitution quantum yield of 1a (Φ = 0.26) was comparable to that of cis-[Ru(bpy)₂(pyridine)₂]²⁺ (Φ = 0.24) in acetonitrile solution. In contrast, the photodissociation of a pzH ligand was strongly suppressed by the deprotonation of a pyrazole ligand N-H group. In the presence of 10 000 equiv of 4,4'-dimethylaminopyridine, the quantum yield dropped to ∼2 × 10^-6 in acetonitrile. The photosubstitution quantum yield of 1b was even smaller than that of neutral complex 1c, although 1c had a smaller HOMO-LUMO energy gap than monocationic complex 1b. The small quantum yield of 1b was attributed to intramolecular hydrogen bonding between pyrazole and pyrazolate ligands. The apparent rate constants for the photosubstitution of 1b were highly solvent-dependent. The photosubstitution of 1b was suppressed in aprotic solvents, while the reaction was accelerated by 2 orders of magnitude in protic solvents with strong proton donor abilities.

Design, synthesis, characterization and evaluation of the anticancer activity of water-soluble half-sandwich ruthenium(ii) arene halido complexes

Synthesis, crystal structure determination, DFT studies, experimental and theoretical evaluation of DNA/BSA interactions and cytotoxicity studies of three piano-stool Ru(ii)(p-cymene)chloride complexes (1–3) are presented herein.

Tetracarboxylate Bis-Bipyridine Ruthenium Dyes: Synthesis, Structural and Electronic Characterisation

The preparation of ruthenium complexes with novel 2,2'-bipyridine (bpy) ligands bearing four carboxylic acid groups was investigated with a view to creating dyes containing more than two potential anchoring groups per bpy unit for attachment to a titania surface. Synthetic challenges are encountered upon using the 2,2'-bipyridine-3,3',4,4'-tetracarboxylic acid ligand because it readily decarboxylates. The use of the methyl esterified derivative (3) proved to be more successful for complex preparation, with a robust preparation of the [Ru(3)₂ Cl₂ ] complex identified with diglyme as the solvent. This complex was further converted into the thiocyanato complex, [Ru(3)₂ (NCS)₂ ], which could not be completely de-esterified. X-ray analysis of crystals obtained from a mixture of isomers for this complex provided data for the S,S- and N,S-coordinated isomers; both showed a twisted arrangement of the pyridine rings in the 2,2'-bipyridine-3,3',4,4'-tetracarboxylic acid ligand, owing to steric hinderance. Conversely, the isosteric 2,2'-bipyridine-4,4',5,5'-tetracarboxylic acid ligand was easily converted into the desired [Ru(2)₂ (NCS)₂ ] complex through a standard one-pot procedure in N,N-dimethylformamide solvent. All of the complexes presented herein exhibit a significant redshift for the metal to ligand charge-transfer bands, relative to the benchmark ruthenium dye N719 and derivatives thereof. All complexes exhibit a quasi-reversible process for the ruthenium(II/III) couple at approximately 0.4 V versus the ferrocene couple, comparable to analogous ruthenium dyes.

Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development

Anticancer metallodrugs based on ruthenium and osmium are among the most investigated and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has undergone considerable advances over the past two decades and has currently two representatives in active clinical trials. As many ruthenium and osmium metallodrugs are prodrugs, a key question to be addressed is how the molecular reactivity of such metal-based therapeutics dictates the selectivity and the type of interaction with molecular targets. Within this frame, this review introduces the field by the examples of the most advanced ruthenium lead structures. Then, global structure-activity relationships are discussed for ruthenium and osmium metallodrugs with respect to in vitro antiproliferative/cytotoxic activity and in vivo tumor-inhibiting properties, as well as pharmacokinetics. Determining and validating global mechanisms of action and molecular targets are still major current challenges. Moreover, significant efforts must be invested in screening in vivo tumor models that mimic human pathophysiology to increase the predictability for successful preclinical and clinical development of ruthenium and osmium metallodrugs.

"Head-to-head" double-hamburger-like structure of di-ruthenated d(GpG) adducts of mono-functional Ru-arene anticancer complexes

Guanine bases in DNA are targets for some Ru-arene anticancer complexes. We have investigated the structure of the novel di-ruthenated d(GpG) adduct Ru₂-GpG (where Ru = {(η⁶-biphenyl)-Ru(en)}²⁺ (1')) in aqueous solution. 2D NMR results indicate that there are two conformers, supported by modeling studies. The major conformer I is a novel double-hamburger-like structure with a "head-to-head" (HH) base arrangement involving hydrophobic interactions between neighboring arene rings, the first example of a HH d(GpG) adduct constructed by weak interactions. Hence there are significant differences compared to Pt-d(GpG) adducts formed by cisplatin. There is no obviously rigid bending for the major conformer I. The minor conformer II of Ru₂-GpG has a back-to-back structure, with two ruthenated guanine bases flipped away from each other. 19-23 base-pair oligodeoxyribonucleotides containing central TGGT sequences di-ruthenated by 1 show no directional bending, only slightly distorted di-ruthenated duplexes, consistent with the NMR data for conformer I. The structural differences and similarities of d(GpG) residues which are di-ruthenated or cross-linked by platination are discussed in the context of the biological activity of these metal complexes.

Perspectives of ruthenium(ii) polyazaaromatic photo-oxidizing complexes photoreactive towards tryptophan-containing peptides and derivatives

This review focuses on recent advances in the search for Ru^II polyazaaromatic complexes as molecular photoreagents for tryptophan-containing peptides and proteins, in view of future biomedical applications.

Rapid screening of photoactivatable metallodrugs: photonic crystal fibre microflow reactor coupled to ESI mass spectrometry

We explore the efficacy of a hyphenated photonic crystal fibre microflow reactor – high-resolution mass spectrometer system as a method for screening the activity of potential new photoactivatable drugs.

We explore the efficacy of a hyphenated photonic crystal fibre microflow reactor – high-resolution mass spectrometer system as a method for screening the activity of potential new photoactivatable drugs. The use of light to activate drugs is an area of current development as it offers the possibility of reduced side effects due to improved spatial and temporal targeting and novel mechanisms of anticancer activity. The di-nuclear ruthenium complex [{(η⁶-indan)RuCl}₂(μ-2,3-dpp)](PF₆)₂, previously studied by Magennis et al. (Inorg. Chem., 2007, 46, 5059) is used as a model drug to compare the system to standard irradiation techniques. The photodecomposition pathways using blue light radiation are the same for PCF and conventional cuvette methods. Reactions in the presence of small biomolecules 5′-guanosine monophosphate (5′-GMP), 5′-adenosine monophosphate (5′-AMP), l-cysteine (l-Cys) and glutathione (γ-l-glutamyl-l-cysteinyl-glycine, GSH) were studied. The complex was found to bind to nucleobases in the dark and this binding increased upon irradiation with 488 nm light, forming the adducts [(η⁶-indan)Ru₂(μ-2,3-dpp) + 5′-GMP]²⁺ and [(η⁶-indan)Ru + (5′-AMP)]⁺. These findings are consistent with studies using conventional methods. The dinuclear complex also binds strongly to GSH after irradiation, a possible explanation for its lack of potency in cell line testing. The use of the PCF-MS system dramatically reduced the sample volume required and reduced the irradiation time by four orders of magnitude from 14 hours to 12 seconds. However, the reduced sample volume also results in a reduced MS signal intensity. The dead time of the combined system is 15 min, limited by the intrinsic dead volume of the HR-MS.

Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies

Ru(ii)-p-Cymene complexes of a bispyrazole-benzimidazole ligand inhibit vascular endothelial growth factor 2, reduce the cellular glutathione pool and inhibit cell migration.

Aminophosphine ligands as a privileged platform for development of antitumoral ruthenium(ii) arene complexes

The potential utility of aminophosphine ligands in both high-throughput testing and rational design of new anticancer metallodrugs.

An upconversion nanoparticle/Ru(ii) polypyridyl complex assembly for NIR-activated release of a DNA covalent-binding agent

A hybrid system is designed to release a DNA covalent-binding agent upon 980 nm laser irradiation.

Development of ruthenium-based complexes as anticancer agents: toward a rational design of alternative receptor targets

In the search for novel anticancer agents, the development of metal-based complexes that could serve as alternatives to cisplatin and its derivatives has received considerable attention in recent years. This becomes necessary because, at present, cisplatin and its derivatives are the only coordination complexes being used as anticancer agents in spite of inherent serious side effects and their limitation against metastasized platinum-resistant cancer cells. Although many metal ions have been considered as possible alternatives to cisplatin, the most promising are ruthenium (Ru) complexes and two Ru compounds, KP1019 and NAMI-A, which are currently in phase II clinical trials. The major obstacle against the rational design of these compounds is the fact that their mode of action in relation to their therapeutic activities and selectivity is not fully understood. There is an urgent need to develop novel metal-based anticancer agents, especially Ru-based compounds, with known mechanism of actions, probable targets, and pharmacodynamic activity. In this paper, we review the current efforts in developing metal-based anticancer agents based on promising Ru complexes and the development of compounds targeting receptors and then examine the future prospects.

Fusion of photodynamic therapy and photoactivated chemotherapy: a novel Ru(II) arene complex with dual activities of photobinding and photocleavage toward DNA

Transition metal complexes with dual functions of DNA photobinding via coordination and DNA photocleavage via(1)O2 may present potent antitumor activities with high selectivity and a wide anticancer spectrum. We herein report such a complex, [(η(6)-p-cymene)Ru(dpb)(py)](2+) (dpb = 2,3-bis(2-pyridyl)benzoquinoxaline, py = pyridine, 1). The highly delocalized nature of dpb provides 1 with long wavelength-absorbing properties and a long-lived excited state, facilitating (1)O2 generation. Additionally, the bulky nature of dpb leads to a distorted coordination geometry, and allow the (3)MC (metal-centered) state to be more accessible. From this, dissociation of py and dpb may occur, followed by the coordination of the resultant Ru fragment to nucleic bases if DNA is present. The dissociation of dpb can turn on fluorescence of its own, enabling real-time imaging of the photoactivation process. The fascinating properties of 1 and the underlying mechanisms that occur may provide guidelines for developing more efficient metallodrugs with dual potential for photodynamic therapy (PDT) and photoactivated chemotherapy (PACT).

Anticancer Activities of Mononuclear Ruthenium(II) Coordination Complexes

Ruthenium compounds are highly regarded as potential drug candidates. The compounds offer the potential of reduced toxicity and can be tolerated in vivo. The various oxidation states, different mechanism of action, and the ligand substitution kinetics of ruthenium compounds give them advantages over platinum-based complexes, thereby making them suitable for use in biological applications. Several studies have focused attention on the interaction between active ruthenium complexes and their possible biological targets. In this paper, we review several ruthenium compounds which reportedly possess promising cytotoxic profiles: from the discovery of highly active compounds imidazolium [trans-tetrachloro(dmso)(imidazole)ruthenate(III)] (NAMI-A), indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)](KP1019), and sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) to the recent work based on both inorganic and organometallic ruthenium(II) compounds. Half-sandwich organometallic ruthenium complexes offer the opportunity of derivatization at the arene moiety, while the three remaining coordination sites on the metal centre can be functionalised with various coordination groups of various monoligands. It is clear from the review that these mononuclear ruthenium(II) compounds represent a strongly emerging field of research that will soon culminate into several ruthenium based antitumor agents.

Anticancer potency studies of coordination driven self-assembled arene–Ru-based metalla-bowls

New tetranuclear cationic metalla-bowls 5–7 with the general formula [Ru4(p-cymene)4(N∩N)2(OO∩OO)2]4+ (N∩N=2,6-bis(N-(4-pyridyl carbamoyl)pyridine, OO∩OO=2,5-dihydroxy-1,4-benzoquinonato (5), OO∩OO=5,8-dioxydo-1,4-naphthaquinonato (6), OO∩OO=hoxonato (7)) were prepared by the reaction of the respective dinuclear ruthenium complexes 2–4 with a bispyridine amide donor ligand 1 in methanol in the presence of AgO3SCF3.These new molecular metalla-bowls were fully characterized by analytical techniques including elemental analysis as well as 1H and 13C NMR and HR-ESI-MS spectroscopy. The structure of metalla-bowl 6 was determined from X-ray crystal diffraction data. A UV/visible study was also carried out for the entire suite of new complexes. As with recent studies of similar arene–Ru complexes, the inhibition of cell growth by metalla-bowls was established against SK-hep-1 (liver cancer), AGS (gastric cancer), and HCT-15 (colorectal cancer) human cancer cell lines. Inhibition of cell growth by 6 was found to be considerably stronger against all cancer cell lines than the anticancer drugs, doxorubicin and cisplatin. In particular, in colorectal cancer cells, expression of the cancer suppressor genes APC and p53 was increased following exposure to 6.

Dinuclear zinc(II) complexes containing (benzimidazol-2-yl)benzene that overcome drug resistance in hepatocellular carcinoma cells through induction of mitochondria fragmentation

Herein we demonstrated that dinuclear zinc complexes could overcome drug resistance in R-HepG2 drug resistance hepatocellular carcinoma cells through induction of mitochondria-mediated apoptosis or by triggering mitochondria fragmentation, depletion of the membrane potential and intracellular ATP levels.

Ru-TAP complexes and DNA: from photo-induced electron transfer to gene photo-silencing in living cells

In this review, examples of applications of the photo-induced electron transfer (PET) process between photo-oxidizing Ru-TAP (TAP = 1,4,5,8-tetraazaphenanthrene) complexes and DNA or oligodeoxynucleotides (ODNs) are discussed. Applications using a free Ru-TAP complex (not chemically anchored to an ODN) are first considered. In this case, the PET gives rise to the production of an irreversible adduct of the Ru complex on a guanine (G) base, with formation of a covalent bond. After absorption of a second photon, this adduct can generate a bi-adduct, whereby the same complex binds to a second G moiety. These bi-adduct formations are responsible for photo-cross-linking between two strands of a duplex, each containing a G base, or between two G moieties of a single strand such as a telomeric sequence, as demonstrated by polyacrylamide gel electrophoresis analyses or mass spectrometry. Scanning force microscopy also allows the detection of such photobridgings with plasmid DNA. Other applications, for example with Ru-ODN, i.e. ODN with chemically anchored Ru-TAP complexes, are also discussed. It is shown that such Ru-ODN probes containing a G base in their own sequences are capable of photo-cross-linking selectively with their targeted complementary sequences, and, in the absence of such targets, they self-photo-inhibit. Such processes are applied successfully in gene photo-silencing of human papillomavirus cancer cells.

Microwave-Assisted Synthesis of Arene Ruthenium(II) Complex as Apoptosis Inducer of A549 Cells

An arene ruthenium(ii) complex coordinated with 2-(2-chlorophenyl)-1H-imidazo[4,5-f][1,10]phenanthroline, [(η6-C6H6)Ru(o-ClPIP)Cl]Cl (1), has been prepared by using microwave-assisted synthesis technology. The anti-tumour activity of this complex against various tumour cells has been evaluated by MTT assay and the results show that complex 1 exhibits selective inhibitory activity against the growth of human lung adenocarcinoma A549 cells with IC50 = 31.58 μM. Further studies by flow cytometric analysis showed that apoptosis of A549 cells was observed when dealt with complex 1. Furthermore, complex 1 exhibits excellent binding affinity with DNA molecules which was confirmed by spectroscopy methods, as well viscosity and melting point experiments. As a result, the conformation of DNA molecules was disturbed by complex 1.

Self-assembled metalla-rectangles bearing azodipyridyl ligands: synthesis, characterization and antitumor activity

Sixteen arene-Ru based molecular-rectangles were self-assembled in high yields by the equimolar mixing of arene-Ru acceptors (Aa-Ad) with various azopyridyl ligands (1,2-di(pyridyl-4yl)diazene (L1), 1,2-bis(pyridin-4-ylmethylene)hydrazine (L2), 1,2-bis(1-(pyridin-4-yl)ethylidene)hydrazine (L3), 1,2-bis(pyridin-4-ylmethylene)hydrazine (L4)) in nitromethane-methanol solutions. These new molecular-rectangles were fully characterized by a host of analytical techniques including elemental analysis, (1)H and (13)C NMR and HR-ESI-MS. The solid-state structures of two molecular-rectangles (1b and 4d) were determined by single crystal X-ray diffraction data. UV-visible and fluorescence studies were also carried out for the entire suite of rectangles. As with recent studies of similar arene-Ru complexes, the anti-proliferative activities of these complexes were evaluated against SK-hep-1 (liver cancer) and A-549 (lung cancer) human cancer lines. Additionally, the cellular pharmacology and intracellular localizations in AGS (gastric cancer) human cancer cells were determined for selected complexes (1c, 1d and 4c) by apoptosis and fluorescence microscopy studies. These studies confirm that arene-Ru molecular-rectangles inhibit cell cycle progression to the G0 phase, in contrast to that of cisplatin which arrests cell growth in the G2 phase.

Photodissociation of a ruthenium(II) arene complex and its subsequent interactions with biomolecules: a density functional theory study

The piano-stool Ru(II) arene complex [(η⁶-benz)Ru(bpm)(py)]²⁺ (benz = benzene, bpm = 2,2'-bipyrimidine, and py = pyridine), which is conventionally nonlabile (on a timescale and under conditions relevant for biological reactivity), can be activated by visible light to selectively photodissociate the monodentate ligand (py). In the present study, the aquation and binding of the photocontrolled ruthenium(II) arene complex [(η⁶-benz)Ru(bpm)(py)]²⁺ to various biomolecules are studied by density functional theory (DFT) and time-dependent DFT (TDDFT). Potential energy curves (PECs) calculated for the Ru-N (py) bonds in [(η⁶-benz)Ru(bpm)(py)]²⁺ in the singlet and triplet state give useful insights into the photodissociation mechanism of py. The binding energies of the various biomolecules are calculated, which allows the order of binding affinities among the considered nuleic-acid- or protein-binding sites to be discerned. The kinetics for the replacement of water in the aqua complex with biomolecules is also considered, and the results demonstrate that guanine is superior to other biomolecules in terms of coordinating with the Ru(II) aqua adduct, which is in reasonable agreement with experimental observations.